Access to anti-retroviral drugs, female in Italy

Italy: Access to anti-retroviral drugs, female was 89.0% in 2023. ▲ Rising

Latest (2023)
89.0%
Change on year
unchanged
World rank
35th
of 141 countries
All-time high
90.0%
in 2019
All-time low
32.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, female in Italy, 2000–2023

0204060801002000201120232000: 32 %2001: 38 %2002: 43 %2003: 48 %2004: 52 %2005: 56 %2006: 60 %2007: 63 %2008: 65 %2009: 68 %2010: 71 %2011: 74 %2012: 80 %2013: 79 %2014: 78 %2015: 80 %2016: 81 %2017: 88 %2018: 89 %2019: 90 %2020: 90 %2021: 89 %2022: 89 %2023: 89 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2023, access to anti-retroviral drugs, female in Italy stood at 89.0%.

The figure is up 12.7% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Italy peaked at 90.0% in 2019 and was at its lowest, 32.0%, in 2000.

That places Italy 35th out of 141 countries with data for 2023, putting it in the top quarter.

The long-run direction has been consistently rising across the 24 years of available data.

Access to anti-retroviral drugs, female in Italy, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Italy, 2000 to 2023.
Year % Change
2000 32.0%
2001 38.0% +18.8%
2002 43.0% +13.2%
2003 48.0% +11.6%
2004 52.0% +8.3%
2005 56.0% +7.7%
2006 60.0% +7.1%
2007 63.0% +5.0%
2008 65.0% +3.2%
2009 68.0% +4.6%
2010 71.0% +4.4%
2011 74.0% +4.2%
2012 80.0% +8.1%
2013 79.0% -1.2%
2014 78.0% -1.3%
2015 80.0% +2.6%
2016 81.0% +1.2%
2017 88.0% +8.6%
2018 89.0% +1.1%
2019 90.0% +1.1%
2020 90.0% +0.0%
2021 89.0% -1.1%
2022 89.0% +0.0%
2023 89.0% +0.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 52.5% 32.0% 68.0% 10
2010s 81.0% 71.0% 90.0% 10
2020s 89.2% 89.0% 90.0% 4

Countries ranked near Italy

  1. 35 Argentina 89.0% compare
  2. 35 Belgium 89.0% compare
  3. 35 Cambodia 89.0% compare
  4. 35 Croatia 89.0% compare
  5. 35 Guinea-Bissau 89.0% compare
  6. 35 Netherlands 89.0% compare
  7. 35 Nigeria 89.0% compare
  8. 35 Spain 89.0% compare

See the full ranking of 160 places →

More gender data for Italy

All data for Italy →

Frequently asked questions

What is access to anti-retroviral drugs, female in Italy?
Access to anti-retroviral drugs, female in Italy was 89.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Italy?
The highest recorded value was 90.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Italy?
The lowest recorded value was 32.0% in 2000.
How does Italy rank for access to anti-retroviral drugs, female?
Italy ranks 35th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, female rising or falling in Italy?
Over the last ten years it is up 12.7%. The long-run trend across the full record is rising.
Where does this Italy data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Italy. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/italy/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/italy/">Access to anti-retroviral drugs, female in Italy</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.